Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University College London
Headquarters: London, United Kingdom
Website: http://www.ucl.ac.uk
Year Founded: 1826
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 27, 2025
Discovery & Translation
Science Spotlight: Clues from the clinic for neoantigen prioritization
BioCentury’s roundup of translational innovations also includes causal biology for a heart condition, and the biological foundational model Evo 2
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Dec 6, 2024
Product Development
KCC2 activation nears inflection point
Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
BioCentury | Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Feb 3, 2024
Discovery & Translation
Science spotlight: RNA-based enzymes for DNA editing; plus XIST-driven autoimmunity and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 14, 2023
Finance
Nov. 13 Quick Takes: Legend finds next CAR partner in Novartis
Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry
BioCentury | Oct 14, 2023
Emerging Company Profile
AstronauTx: targeting astrocytes to treat neurodegenerative diseases
London, U.K.-based company aims to clear a wide array of toxic proteins out of the brain, and is settings it first sights on Alzheimer’s disease
BioCentury | Jul 13, 2023
Emerging Company Profile
Tenpoint: a toolbox of ex vivo and in vivo treatments for vision loss
F-Prime, Sofinnova, British Patient Capital invest $70M in company with ex vivo stem cell and in vivo cell reprogramming platforms
BioCentury | May 15, 2023
Emerging Company Profile
Adrestia’s synthetic rescue approach to genetic diseases
Cambridge spinout and GSK partner leveraging founder Steve Jackson’s DNA damage response expertise, outside of cancer
Items per page:
1 - 10 of 315